Bio-Gate AG

BIG1

Equity

ISIN DE000BGAG981 / Valor 20104373

Xetra (2024-09-16)

EUR 0.87%

Bio-Gate AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

ntiviral properties into everyday products such as textiles, cosmetics, and household items. Bio-Gate AG's core technology, MicroSilver BG™, is an antimicrobial and antiviral additive that can be integrated into various materials and formulations to enhance their performance. The company's focus is on improving health and hygiene by providing innovative solutions that contribute to a safer and healthier living environment for individuals and animals. In particular, Bio-Gate AG specializes in the medical technology sector, offering solutions for medical implants, wound dressings, and other healthcare products.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In the first quarter of 2023, Bio-Gate AG reported a significant increase in revenue, reaching 7.2 million euros. This marks a notable improvement compared to the previous year's figures, reflecting the company's successful expansion in various business segments.

Profitability

Bio-Gate AG managed to reduce its consolidated annual net loss to 1.6 million euros in Q1 2023. This reduction in losses indicates a positive trend towards achieving profitability, driven by increased sales and effective cost management strategies.

Liquidity Position

As of December 31, 2023, Bio-Gate AG's liquidity stood at 1.3 million euros. This stable liquidity position ensures that the company has sufficient funds to support its ongoing operations and future growth initiatives.

Dermakosmetik and Wound Care

The dermakosmetik and wound care segment for the human sector remained the largest revenue contributor for Bio-Gate AG in Q1 2023. This segment saw a growth of over 35%, generating more than 3.93 million euros in revenue, highlighting the strong demand for these products.

Outlook for 2024

Bio-Gate AG's management is optimistic about the company's growth prospects for 2024. They anticipate a significant increase in revenue, along with a marked improvement in EBITDA and overall group results, provided there are no major economic disruptions or delays in development projects.

Summarized from source with an LLMView Source

Key figures

-8.42%1Y

-78.6%3Y

%5Y

Performance

92.7%1Y

70.7%3Y

69.8%5Y

Volatility